Capital Research Global Investors Astrazeneca PLC Transaction History
Capital Research Global Investors
- $466 Billion
- Q4 2024
A detailed history of Capital Research Global Investors transactions in Astrazeneca PLC stock. As of the latest transaction made, Capital Research Global Investors holds 767,728 shares of AZN stock, worth $57.9 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
767,728
Previous 1,080,218
28.93%
Holding current value
$57.9 Million
Previous $84.2 Million
40.24%
% of portfolio
0.01%
Previous 0.02%
Shares
8 transactions
Others Institutions Holding AZN
# of Institutions
1,358Shares Held
512MCall Options Held
6.08MPut Options Held
4.44M-
Price T Rowe Associates Inc Baltimore, MD60.4MShares$4.55 Billion0.46% of portfolio
-
Primecap Management CO Pasadena, CA41MShares$3.09 Billion2.12% of portfolio
-
Capital International Investors Los Angeles, CA37.5MShares$2.83 Billion0.48% of portfolio
-
Wellington Management Group LLP Boston, MA37MShares$2.79 Billion0.46% of portfolio
-
Bank Of America Corp Charlotte, NC24MShares$1.81 Billion0.13% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $234B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...